TrialMedical oncology (Northwood, London, England)2018

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.

Ryoma Igarashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.